207 related articles for article (PubMed ID: 20968204)
21. [Treatment of ascites, hyponatremia and hepatorenal syndrome in liver cirrhosis].
Ackermann D
Ther Umsch; 2009 Nov; 66(11):747-51. PubMed ID: 19885792
[TBL] [Abstract][Full Text] [Related]
22. [Influence of circulatory dysfunction on the treatment of ascites and hepatorenal syndrome: vasoconstrictor and diuretic drug treatment].
Torre A; Terra C; Guevara M; Ginès P
Gastroenterol Hepatol; 2004 Feb; 27 Suppl 1():8-14. PubMed ID: 15195529
[No Abstract] [Full Text] [Related]
23. Haemodynamic changes in portal hypertension: new insights in the pathogenesis and clinical implications.
Michielsen PP; Pelckmans PA
Acta Gastroenterol Belg; 1994; 57(2):194-205. PubMed ID: 8053307
[TBL] [Abstract][Full Text] [Related]
24. Review: the controversy over the pathophysiology of ascites formation in cirrhosis.
Wong F; Girgrah N; Blendis L
J Gastroenterol Hepatol; 1997 Jun; 12(6):437-44. PubMed ID: 9195401
[TBL] [Abstract][Full Text] [Related]
25. [Natural course and physiopathology of ascites in the cirrhotic patient].
Bernardi M; Colantoni A; Caraceni P; Sica G; Trevisani F
Ann Ital Med Int; 1996 Oct; 11 Suppl 2():30S-38S. PubMed ID: 9004818
[TBL] [Abstract][Full Text] [Related]
26. [Hyponatremia in liver cirrhosis: pathogenesis and treatment].
Guevara M; Ginès P
Endocrinol Nutr; 2010 May; 57 Suppl 2():15-21. PubMed ID: 21130958
[TBL] [Abstract][Full Text] [Related]
27. Effects of nitric oxide inhibition by methylene blue in cirrhotic patients with ascites.
Kalambokis G; Economou M; Fotopoulos A; Bokharhii JA; Christos P; Paraskevi K; Konstantinos P; Katsaraki A; Tsianos EV
Dig Dis Sci; 2005 Oct; 50(10):1771-7. PubMed ID: 16187171
[TBL] [Abstract][Full Text] [Related]
28. Prognostic markers in patients with ascites and hepatorenal syndrome.
Nazal L; Cárdenas A
Dis Markers; 2011; 31(3):139-46. PubMed ID: 22045399
[No Abstract] [Full Text] [Related]
29. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis.
Schrier RW; Arroyo V; Bernardi M; Epstein M; Henriksen JH; Rodés J
Hepatology; 1988; 8(5):1151-7. PubMed ID: 2971015
[TBL] [Abstract][Full Text] [Related]
30. Splanchnic and systemic vasodilatation: the patient.
Tsai MH
J Clin Gastroenterol; 2007; 41 Suppl 3():S266-71. PubMed ID: 17975476
[TBL] [Abstract][Full Text] [Related]
31. [Dilutional hyponatremia, hepatorenal syndrome and liver transplantation].
Cárdenas A; Ginès P
Gastroenterol Hepatol; 2008 Jan; 31(1):29-36. PubMed ID: 18218278
[TBL] [Abstract][Full Text] [Related]
32. Hepatorenal syndrome.
Biswas KD; Jain AK
Trop Gastroenterol; 2002; 23(3):113-6. PubMed ID: 12693150
[TBL] [Abstract][Full Text] [Related]
33. Cardiovascular and renal effects of low-dose atrial natriuretic peptide in compensated cirrhosis.
La Villa G; Lazzeri C; Pascale A; Sestini S; Bisi G; Sciagrà R; Vecchiarino S; Raggi VC; Barletta G; Laffi G; Gentilini P
Am J Gastroenterol; 1997 May; 92(5):852-7. PubMed ID: 9149200
[TBL] [Abstract][Full Text] [Related]
34. Emerging hepatic syndromes: pathophysiology, diagnosis and treatment.
Bertino G; Privitera G; Purrello F; Demma S; Crisafulli E; Spadaro L; Koukias N; Tsochatzis EA
Intern Emerg Med; 2016 Oct; 11(7):905-16. PubMed ID: 27273018
[TBL] [Abstract][Full Text] [Related]
35. Pathophysiology of ascites and dilutional hyponatremia: contemporary use of aquaretic agents.
Leiva JG; Salgado JM; Estradas J; Torre A; Uribe M
Ann Hepatol; 2007; 6(4):214-21. PubMed ID: 18007550
[TBL] [Abstract][Full Text] [Related]
36. Review article: pathogenesis and pathophysiology of hepatorenal syndrome--is there scope for prevention?
Møller S; Henriksen JH
Aliment Pharmacol Ther; 2004 Sep; 20 Suppl 3():31-41; discussion 42-3. PubMed ID: 15335398
[TBL] [Abstract][Full Text] [Related]
37. Pathogenetic factors and clinical elements in ascites and hepatorenal syndrome during liver cirrhosis.
Gentilini P; Laffi G; La Villa G; Raggi VC
Ann Ital Med Int; 1999; 14(4):264-84. PubMed ID: 10638019
[TBL] [Abstract][Full Text] [Related]
38. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.
Angeli P; Volpin R; Piovan D; Bortoluzzi A; Craighero R; Bottaro S; Finucci GF; Casiglia E; Sticca A; De Toni R; Pavan L; Gatta A
Hepatology; 1998 Oct; 28(4):937-43. PubMed ID: 9755229
[TBL] [Abstract][Full Text] [Related]
39. Challenges and Management of Liver Cirrhosis: Pathophysiology of Renal Dysfunction in Cirrhosis.
Solà E; Ginès P
Dig Dis; 2015; 33(4):534-8. PubMed ID: 26159270
[TBL] [Abstract][Full Text] [Related]
40. Ascites and hepatorenal syndrome: pathophysiology and management.
Roberts LR; Kamath PS
Mayo Clin Proc; 1996 Sep; 71(9):874-81. PubMed ID: 8790265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
